Oct 26 (Reuters) - Revive Therapeutics Ltd RVV.V :
* Announces US FDA grants orphan drug designation for bucillamine for the
treatment of cystinuria
* Says the orphan drug designation will provide a seven-year period of
marketing exclusivity in the U.S. to Revive
* Source text for Eikon urn:newsml:reuters.com:*:nCCN7W5cYy
* Further company coverage RVV.V